Developer docs
API playgroundTry for free, no card

Search company profiles

Akouos

Full company profile

uuid0003vjs

Namestring
Akouos
Legal namestring
Akouos, Inc.
Websiteurl
akouos.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Akouos is a clinical-stage precision genetic medicine company developing adeno-associated virus (AAV) vector-based gene therapies targeting genetically driven forms of hearing loss and inner ear disorders. Founded in 2016 and headquartered in Boston, Massachusetts, the company builds on the Ancestral AAV (AAVAnc) Technology platform — exclusively licensed for inner ear applications from co-founder Dr. Luk H. Vandenberghe's laboratory at Massachusetts Eye and Ear — combined with a proprietary minimally invasive transcanal delivery approach designed to achieve consistent vector distribution along the cochlear sensory epithelium. Its portfolio includes lead candidate AK-OTOF (AAV gene therapy delivering a healthy otoferlin gene for OTOF-mediated hearing loss, currently in Phase 1/2), AK-antiVEGF (Phase 1/2 in vestibular schwannoma), and earlier-stage programs targeting CLRN1 (Usher Syndrome Type 3A), GJB2, autosomal dominant hearing loss, and hair cell regeneration.

The company's revenue model is presently that of a clinical-stage biotech with no commercial products: near-term value is realized through clinical advancement and eventual commercialization of gene therapy products, while the company also operates ancillary assets such as the Resonate no-charge genetic testing and counseling program (US, Brazil, Mexico) and The Sing Registry for genetic sensorineural hearing loss. Following Eli Lilly's October 2022 acquisition announcement (approximately $487 million upfront plus contingent milestone payments) and the November 2022 tender offer expiration, Akouos operates as a wholly owned subsidiary of Eli Lilly, with future commercial distribution expected to leverage Lilly's global pharmaceutical infrastructure.

Customer segmentation is structured around narrow genetic patient populations rather than enterprise accounts, with primary focus on OTOF-mediated hearing loss patients (severe-to-profound bilateral congenital hearing loss), followed by vestibular schwannoma, Usher Syndrome Type 3A, and GJB2-mediated hearing loss populations. Go-to-market centers on FDA regulatory pathways — AK-OTOF has received FDA Orphan Drug Designation, FDA Rare Pediatric Disease Designation, and European Commission Orphan Drug Designation — supplemented by patient advocacy partnerships (AG Bell, Hearing Loss Association of America, Global Genes, Usher Syndrome Society) and direct patient recruitment via dedicated clinical trial websites.

Short descriptiontext

Akouos is a clinical-stage precision genetic medicine company developing AAV-based gene therapies for genetically driven hearing loss, with lead program AK-OTOF in Phase 1/2 trials. It operates as a wholly owned subsidiary of Eli Lilly following a 2022 acquisition.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, precision genetic medicine, inner ear therapeutics, AAV gene therapies, hearing loss treatments
Industry4 codes
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)
SECONDARYHLAKAMAI
Audiology & Hearing Services (ENT-Affiliated)
SECONDARYHLAFAKAH
Audiology & Hearing Diagnostic Centers
SECONDARYHLAKAMAB
Pediatric Otolaryngology
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Health Services8000
Product category
Gene Therapy for Hearing Loss
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Pipeline
TypeOne Time License
Description

Akouos is a clinical-stage precision genetic medicine company focused on developing AAV gene therapies for hearing loss. The company was acquired by Eli Lilly in October 2022 for approximately $487 million upfront with potential for additional milestone payments. As a wholly owned subsidiary, Akouos operates within Lilly's broader pharmaceutical portfolio. Revenue generation would come from FDA-approved gene therapy products following successful clinical development.

akouos.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Resonate
Description

A no-charge genetic testing and counseling program for sensorineural hearing loss using a comprehensive panel of nearly 300 genes.

akouos.com
Core offering1 text field

Akouos is a clinical-stage precision genetic medicine company developing AAV vector-based gene therapies designed to restore, improve, and preserve hearing in patients with genetically defined inner ear disorders. Its lead programs are AK-OTOF, an intra-cochlear AAV gene therapy for OTOF-mediated hearing loss currently in Phase 1/2 clinical trials, and AK-antiVEGF for vestibular schwannoma also in Phase 1/2, with additional earlier-stage programs targeting CLRN1 (Usher Syndrome Type 3A), GJB2, autosomal dominant hearing loss, and hair cell regeneration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 466 million people worldwide have disabling hearing loss with no FDA-approved pharmacologic therapies addressing underlying causes
+1 more record
Product overview1 text field

Akouos is a precision genetic medicine company developing a portfolio of AAV vector-based gene therapies targeting inner ear disorders. The company's core programs include AK-OTOF (lead program for OTOF-mediated hearing loss, in Phase 1/2), AK-antiVEGF (for vestibular schwannoma, in Phase 1/2), CLRN1 (for Usher Syndrome Type 3A), GJB2-mediated hearing loss, autosomal dominant hearing loss, and hair cell regeneration. The company also offers Resonate, a genetic testing and counseling program for sensorineural hearing loss, and maintains The Sing Registry for patient data. Akouos operates as a wholly owned subsidiary of Eli Lilly and Company following an October 2022 acquisition.

Product and service7 records
1AK-OTOF
CategoryGene Therapy
Description

Adeno-associated virus (AAV) gene therapy for OTOF-mediated hearing loss, designed to deliver a healthy copy of the otoferlin gene to cochlear hair cells following a single inner ear administration to restore hearing. Currently in Phase 1/2 clinical trials in children with OTOF-mediated hearing loss and has received FDA Orphan Drug, FDA Rare Pediatric Disease, and European Commission Orphan Drug designations.

2AK-antiVEGF
CategoryGene Therapy
Description

AAV gene therapy for vestibular schwannoma (acoustic neuroma) that delivers DNA sequences encoding anti-VEGF proteins to block tumor growth and preserve hearing. Currently in Phase 1/2 clinical trial.

3CLRN1 Program
CategoryGene Therapy
Description

Gene therapy development program targeting Usher Syndrome Type 3A caused by CLRN1 gene mutations, designed to treat both hearing and vision components of the syndrome via hair cell targeting.

4GJB2 Program
CategoryGene Therapy
Description

Gene therapy development program targeting GJB2-mediated hearing loss (connexin 26 mutations), addressing one of the most common genetic causes of congenital hearing loss by targeting supporting cells in the cochlea.

5Autosomal Dominant Hearing Loss Program
CategoryGene Therapy
Description

Gene therapy development program for autosomal dominant hearing loss using AAV-enabled gene transfer combined with knockdown mechanisms to address dominant-negative mutations.

6Hair Cell Regeneration Program
CategoryResearch Program
Description

Research program targeting supporting cells in the cochlea with the goal of regenerating inner ear hair cells to address hearing loss beyond monogenic causes.

7Resonate by Akouos
CategoryGenetic Testing Service
Description

No-charge genetic testing and counseling program using a comprehensive panel of nearly 300 genes to identify genetic causes of sensorineural hearing loss; available to providers in the U.S., Brazil, and Mexico.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-11
Description

Akouos and Blueprint Genetics announced the Resonate program to improve access to genetic testing for individuals with auditory neuropathy. Resonate is a no-charge genetic testing and counseling program sponsored by Akouos using a comprehensive panel of nearly 300 genes to potentially determine whether there is an underlying genetic cause of hearing loss. The program is available for providers in the U.S., Brazil, and Mexico.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Akouos's parent company since November 2022. Broad incumbent providing global pharma infrastructure and acting as ultimate decision-maker on Akouos's pipeline strategy and capital allocation.

TypeDirect peer
Description

Clinical-stage biotech developing AAV-based gene therapies for hearing and balance disorders, including OTOF programs. Acquired by Regeneron in 2023. Closest direct competitor in the inner-ear gene therapy category.

TypeDirect peer
Description

Clinical-stage biotech focused on hearing restoration through small-molecule activation of inner-ear progenitor cells. Direct peer in the broader hearing-loss therapeutics category, though using a different modality (small molecule vs. AAV).

TypeDirect peer
Description

Clinical-stage European biotech developing therapies for hearing loss disorders, including genetic and vestibular indications. Comparable in therapeutic focus on inner-ear disorders and rare-disease strategy.

5Otonomy
TypeDirect peer
Description

Clinical-stage biotech developing sustained-exposure drug therapies for ear disorders including hearing loss and tinnitus. Direct peer in clinical-stage otology drug development with a similar focus on inner-ear delivery.

TypeEmerging player
Description

Clinical-stage biotech developing regenerative therapies for hearing loss, including hair-cell regeneration approaches. Comparable in target indication (sensorineural hearing loss) and pipeline stage though with a non-AAV modality.

TypeBroad incumbent
Description

Large biotech with a growing gene therapy franchise, including its 2023 acquisition of Decibel Therapeutics. Broad incumbent with overlapping capabilities in genetic medicine and direct hearing-loss ambitions.

TypeBroad incumbent
Description

Clinical-stage gene therapy company developing AAV-based therapies for CNS disorders. Comparable in AAV platform technology and gene therapy development expertise, though targeting different therapeutic areas.

TypeBroad incumbent
Description

Large Japanese pharma that acquired Audion Therapeutics to pursue inner-ear regenerative therapies for hearing loss. Broad incumbent with direct overlap in hearing-loss therapeutics ambitions.

TypeOthers
Description

Global leader in cochlear implant devices for severe-to-profound hearing loss. Not a gene-therapy competitor, but the dominant existing intervention for the same patient populations Akouos ultimately aims to address — and a key benchmark for treatment-center access.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Akouos

Gene Therapy for Hearing Lossakouos.com

Akouos is a clinical-stage precision genetic medicine company developing AAV-based gene therapies for genetically driven hearing loss, with lead program AK-OTOF in Phase 1/2 trials. It operates as a wholly owned subsidiary of Eli Lilly following a 2022 acquisition.

What Akouos does

Akouos is a clinical-stage precision genetic medicine company developing adeno-associated virus (AAV) vector-based gene therapies targeting genetically driven forms of hearing loss and inner ear disorders. Founded in 2016 and headquartered in Boston, Massachusetts, the company builds on the Ancestral AAV (AAVAnc) Technology platform — exclusively licensed for inner ear applications from co-founder Dr. Luk H. Vandenberghe's laboratory at Massachusetts Eye and Ear — combined with a proprietary minimally invasive transcanal delivery approach designed to achieve consistent vector distribution along the cochlear sensory epithelium. Its portfolio includes lead candidate AK-OTOF (AAV gene therapy delivering a healthy otoferlin gene for OTOF-mediated hearing loss, currently in Phase 1/2), AK-antiVEGF (Phase 1/2 in vestibular schwannoma), and earlier-stage programs targeting CLRN1 (Usher Syndrome Type 3A), GJB2, autosomal dominant hearing loss, and hair cell regeneration.

The company's revenue model is presently that of a clinical-stage biotech with no commercial products: near-term value is realized through clinical advancement and eventual commercialization of gene therapy products, while the company also operates ancillary assets such as the Resonate no-charge genetic testing and counseling program (US, Brazil, Mexico) and The Sing Registry for genetic sensorineural hearing loss. Following Eli Lilly's October 2022 acquisition announcement (approximately $487 million upfront plus contingent milestone payments) and the November 2022 tender offer expiration, Akouos operates as a wholly owned subsidiary of Eli Lilly, with future commercial distribution expected to leverage Lilly's global pharmaceutical infrastructure.

Customer segmentation is structured around narrow genetic patient populations rather than enterprise accounts, with primary focus on OTOF-mediated hearing loss patients (severe-to-profound bilateral congenital hearing loss), followed by vestibular schwannoma, Usher Syndrome Type 3A, and GJB2-mediated hearing loss populations. Go-to-market centers on FDA regulatory pathways — AK-OTOF has received FDA Orphan Drug Designation, FDA Rare Pediatric Disease Designation, and European Commission Orphan Drug Designation — supplemented by patient advocacy partnerships (AG Bell, Hearing Loss Association of America, Global Genes, Usher Syndrome Society) and direct patient recruitment via dedicated clinical trial websites.

Akouos firmographics

Firmographics
Name
Akouos
Legal name
Akouos, Inc.
Website
https://akouos.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
11–50 employees
Short description
Akouos is a clinical-stage precision genetic medicine company developing AAV-based gene therapies for genetically driven hearing loss, with lead program AK-OTOF in Phase 1/2 trials. It operates as a wholly owned subsidiary of Eli Lilly following a 2022 acquisition.
Ownership category
akta.pro rank

Akouos industry classification

Industry
Product category
Gene Therapy for Hearing Loss
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)
SECONDARYHLAKAMAI
Audiology & Hearing Services (ENT-Affiliated)
SECONDARYHLAFAKAH
Audiology & Hearing Diagnostic Centers
SECONDARYHLAKAMAB
Pediatric Otolaryngology

Keywords

  • Gene therapy development
  • Precision genetic medicine
  • Inner ear therapeutics
  • AAV gene therapies
  • Hearing loss treatments

Where Akouos is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Akouos business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Gene Therapy Pipeline: Akouos is a clinical-stage precision genetic medicine company focused on developing AAV gene therapies for hearing loss. The company was acquired by Eli Lilly in October 2022 for approximately $487 million upfront with potential for additional milestone payments. As a wholly owned subsidiary, Akouos operates within Lilly's broader pharmaceutical portfolio. Revenue generation would come from FDA-approved gene therapy products following successful clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Akouos product offering

Product offering

Core offering

Akouos is a clinical-stage precision genetic medicine company developing AAV vector-based gene therapies designed to restore, improve, and preserve hearing in patients with genetically defined inner ear disorders. Its lead programs are AK-OTOF, an intra-cochlear AAV gene therapy for OTOF-mediated hearing loss currently in Phase 1/2 clinical trials, and AK-antiVEGF for vestibular schwannoma also in Phase 1/2, with additional earlier-stage programs targeting CLRN1 (Usher Syndrome Type 3A), GJB2, autosomal dominant hearing loss, and hair cell regeneration.

Product overview

Akouos is a precision genetic medicine company developing a portfolio of AAV vector-based gene therapies targeting inner ear disorders. The company's core programs include AK-OTOF (lead program for OTOF-mediated hearing loss, in Phase 1/2), AK-antiVEGF (for vestibular schwannoma, in Phase 1/2), CLRN1 (for Usher Syndrome Type 3A), GJB2-mediated hearing loss, autosomal dominant hearing loss, and hair cell regeneration. The company also offers Resonate, a genetic testing and counseling program for sensorineural hearing loss, and maintains The Sing Registry for patient data. Akouos operates as a wholly owned subsidiary of Eli Lilly and Company following an October 2022 acquisition.

Differentiator

Problem solved

Functional benefit

Brands

  • Resonate: A no-charge genetic testing and counseling program for sensorineural hearing loss using a comprehensive panel of nearly 300 genes.

Products and services

  • AK-OTOF Adeno-associated virus (AAV) gene therapy for OTOF-mediated hearing loss, designed to deliver a healthy copy of the otoferlin gene to cochlear hair cells following a single inner ear administration to restore hearing. Currently in Phase 1/2 clinical trials in children with OTOF-mediated hearing loss and has received FDA Orphan Drug, FDA Rare Pediatric Disease, and European Commission Orphan Drug designations.
  • AK-antiVEGF AAV gene therapy for vestibular schwannoma (acoustic neuroma) that delivers DNA sequences encoding anti-VEGF proteins to block tumor growth and preserve hearing. Currently in Phase 1/2 clinical trial.
  • CLRN1 Program Gene therapy development program targeting Usher Syndrome Type 3A caused by CLRN1 gene mutations, designed to treat both hearing and vision components of the syndrome via hair cell targeting.
  • GJB2 Program Gene therapy development program targeting GJB2-mediated hearing loss (connexin 26 mutations), addressing one of the most common genetic causes of congenital hearing loss by targeting supporting cells in the cochlea.
  • Autosomal Dominant Hearing Loss Program Gene therapy development program for autosomal dominant hearing loss using AAV-enabled gene transfer combined with knockdown mechanisms to address dominant-negative mutations.
  • Hair Cell Regeneration Program Research program targeting supporting cells in the cochlea with the goal of regenerating inner ear hair cells to address hearing loss beyond monogenic causes.
  • Resonate by Akouos No-charge genetic testing and counseling program using a comprehensive panel of nearly 300 genes to identify genetic causes of sensorineural hearing loss; available to providers in the U.S., Brazil, and Mexico.

Quantifiable outcome

  • 466 million people worldwide have disabling hearing loss with no FDA-approved pharmacologic therapies addressing underlying causes
  • +1 more outcomes

Companies that use Akouos

Customer profile

Segments4 records

Ideal customer profiles3 records

Akouos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Akouos partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Blueprint GeneticsminorStrategic or Co-development Partner · 11 January 2021Akouos and Blueprint Genetics announced the Resonate program to improve access to genetic testing for individuals with auditory neuropathy. Resonate is a no-charge genetic testing and counseling program sponsored by Akouos using a comprehensive panel of nearly 300 genes to potentially determine whether there is an underlying genetic cause of hearing loss. The program is available for providers in the U.S., Brazil, and Mexico.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Akouos competitors and assessment

Company assessment

Broad incumbents

  • Eli Lilly and Company: Akouos's parent company since November 2022. Broad incumbent providing global pharma infrastructure and acting as ultimate decision-maker on Akouos's pipeline strategy and capital allocation.
  • Regeneron Pharmaceuticals: Large biotech with a growing gene therapy franchise, including its 2023 acquisition of Decibel Therapeutics. Broad incumbent with overlapping capabilities in genetic medicine and direct hearing-loss ambitions.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for CNS disorders. Comparable in AAV platform technology and gene therapy development expertise, though targeting different therapeutic areas.
  • Astellas Pharma: Large Japanese pharma that acquired Audion Therapeutics to pursue inner-ear regenerative therapies for hearing loss. Broad incumbent with direct overlap in hearing-loss therapeutics ambitions.

Direct peers

  • Decibel Therapeutics: Clinical-stage biotech developing AAV-based gene therapies for hearing and balance disorders, including OTOF programs. Acquired by Regeneron in 2023. Closest direct competitor in the inner-ear gene therapy category.
  • Frequency Therapeutics: Clinical-stage biotech focused on hearing restoration through small-molecule activation of inner-ear progenitor cells. Direct peer in the broader hearing-loss therapeutics category, though using a different modality (small molecule vs. AAV).
  • Sensorion: Clinical-stage European biotech developing therapies for hearing loss disorders, including genetic and vestibular indications. Comparable in therapeutic focus on inner-ear disorders and rare-disease strategy.
  • Otonomy: Clinical-stage biotech developing sustained-exposure drug therapies for ear disorders including hearing loss and tinnitus. Direct peer in clinical-stage otology drug development with a similar focus on inner-ear delivery.

Emerging players

  • Pipeline Therapeutics: Clinical-stage biotech developing regenerative therapies for hearing loss, including hair-cell regeneration approaches. Comparable in target indication (sensorineural hearing loss) and pipeline stage though with a non-AAV modality.

Others

  • Cochlear Limited: Global leader in cochlear implant devices for severe-to-profound hearing loss. Not a gene-therapy competitor, but the dominant existing intervention for the same patient populations Akouos ultimately aims to address — and a key benchmark for treatment-center access.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Akouos social profiles

Digital presence

Akouos compliance and trust

Trust signal

Compliance2 records

Akouos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Akouos leadership team

Management profile

Number of profiles

Profiles9 records

Akouos funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Akouos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akouos

What does Akouos do?

Akouos is a clinical-stage precision genetic medicine company developing AAV vector-based gene therapies designed to restore, improve, and preserve hearing in patients with genetically defined inner ear disorders. Its lead programs are AK-OTOF, an intra-cochlear AAV gene therapy for OTOF-mediated hearing loss currently in Phase 1/2 clinical trials, and AK-antiVEGF for vestibular schwannoma also in Phase 1/2, with additional earlier-stage programs targeting CLRN1 (Usher Syndrome Type 3A), GJB2, autosomal dominant hearing loss, and hair cell regeneration.

Is Akouos a public or private company?

Akouos is a private company. It is classified as corporate owned and is currently acquired.

When was Akouos founded?

Akouos was founded in 2016. It employs 11 to 50 people.

Where is Akouos based?

Akouos is headquartered in Boston, United States, in the North America region.

How does Akouos make money?

One revenue line is on record: gene Therapy Pipeline.

Who are Akouos's main competitors?

Broad incumbents on record are Eli Lilly and Company, Regeneron Pharmaceuticals, Voyager Therapeutics and Astellas Pharma. Direct peers are Decibel Therapeutics, Frequency Therapeutics, Sensorion and Otonomy. Pipeline Therapeutics is listed as an emerging player. Cochlear Limited is listed as an others.

Does Akouos have an API?

No public API is recorded for Akouos.

What industry is Akouos in?

Akouos's product category is Gene Therapy for Hearing Loss. Its primary akta.pro industry code is HLAKAMAC, Otology & Neurotology (Ear/Hearing/Balance), with a secondary code of HLAKAMAI, Audiology & Hearing Services (ENT-Affiliated). Its NAICS code is 541714 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Built In Boston15 Biotech Companies in Boston Saving the Day in 2025The article highlights Boston's dominance in the biotech sector, specifically noting that its Kendall Square neighborhood hosts numerous companies within a small radius. It profiles Biofourmis, which uses AI and wearables for chronic disease treatment with operations in Singapore, Bengaluru, and Zurich, and Akouos, which focuses on hearing preservation technology and gene therapy.PR NewswireLilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic DiseasesEli Lilly and Company completed its acquisition of Akouos, Inc., expanding its genetic medicine portfolio to include adeno-associated viral gene therapies for inner ear conditions. The transaction involved a cash consideration of $12.50 per share plus contingent value rights, with Akouos becoming a wholly owned subsidiary of Lilly. This move integrates Akouos's pipeline into Lilly's Institute for Genetic Medicine to accelerate the development of treatments for sensorineural hearing loss.PR NewswireLilly and Akouos Announce Expiration of Akouos Tender OfferEli Lilly and Company and Akouos, Inc. announced that Lilly's tender offer to acquire all outstanding shares of Akouos expired as scheduled at 11:59 p.m. Eastern time on November 29, 2022, with 29,992,668 shares validly tendered representing 81.1% of outstanding shares. All conditions to the offer have been satisfied, and Lilly and its subsidiary Kearny Acquisition Corporation have accepted the tendered shares and will promptly pay $12.50 per share in cash plus one non-tradable contingent value right worth up to $3.00 per share upon milestone achievement. The acquisition is expected to close on December 1, 2022, subject to final terms of the definitive agreement.PR NewswireSHAREHOLDER ALERT: Weiss Law Reminds LBC, AERC, AKUS, and ABMD Shareholders About Its Ongoing InvestigationsWeiss Law is investigating possible breaches of fiduciary duty and other violations of law by the boards of directors of Luther Burbank Corporation, AeroClean Technologies, Inc., Akouos, Inc., and Abiomed, Inc. in connection with their respective merger or acquisition transactions. The investigations focus on the terms of the proposed mergers and tender offers, which included stock exchanges and cash payments to shareholders. These investigations signal potential legal complexities surrounding corporate governance in major transactions involving these companies.PR NewswireAKOUOS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akouos, Inc. - AKUSKahn Swick & Foti, LLC is investigating the adequacy of price and process in the proposed sale of Akouos, Inc. to Eli Lilly and Company. Under the transaction terms, Akouos shareholders are set to receive $12.50 in cash plus one contingent value right for each share.PR NewswireINVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Akouos, Inc. - AKUSMonteverde & Associates PC announced an investigation into Akouos, Inc. regarding its proposed acquisition by Eli Lilly and Company. The tender offer terms stipulate that AKUS shareholders will receive $12.50 in cash plus one Contingent Value Right (CVR) potentially worth up to $3.00 per share. This legal action aims to protect shareholder interests during the merger process.PR NewswireSHAREHOLDER ALERT: Weiss Law Investigates Akouos, Inc.Weiss Law announced an investigation into Akouos, Inc.'s board of directors regarding a proposed tender offer by Eli Lilly and Company, under which shareholders would receive $12.50 in cash plus one contingent value right of up to $3.00 per share. The law firm is examining whether the board acted in shareholders' best interests, whether the merger consideration adequately compensates shareholders, and whether full disclosure was made regarding the transaction's sales process and valuation. The investigation was prompted by concerns that the $12.50 per-share offer is significantly below the $25 median analyst price target and the $35 price target set by at least one analyst.Chemical & Engineering NewsLilly to acquire hearing loss company AkouosEli Lilly and Company is acquiring Boston-based Akouos for $487 million, with potential additional payments of up to $123 million contingent on clinical trial milestones. The acquisition expands Lilly's presence in genetic medicine and targets the development of gene therapies for otoferlin deficiency, a congenital form of hearing loss.BenzingaCrude Oil Drops Over 2%; Akouos Shares Spike Higher - ADS-TEC Energy (NASDAQ:ADSE)U.S. stock indices closed higher on Tuesday, with the Dow gaining 1.02%, the NASDAQ rising 0.57%, and the S&P 500 up 0.94%, while Goldman Sachs reported quarterly sales of $11.98 billion, beating market estimates of $11.43 billion. Notable M&A activity included Eli Lilly acquiring Akouos for a 78% premium and LG Chem announcing the acquisition of AVEO Oncology for $15 per share in cash. Crude oil dropped 2.2% to $83.56, and the NAHB housing market index fell for the 10th consecutive month to 38.